<DOC>
	<DOCNO>NCT03030287</DOCNO>
	<brief_summary>The purpose study test efficacy safety experimental drug , OMP-305B83 , give combination paclitaxel . OMP-305B83 humanized monoclonal antibody develop target cancer stem cell . Based preclinical study , believe OMP-305B83 may block growth cancer stem cell may also impair productive growth new blood vessel , tumor need grow spread .</brief_summary>
	<brief_title>A Phase 1b Study OMP-305B83 Plus Paclitaxel Subjects With Ovarian , Peritoneal Fallopian Tube Cancer</brief_title>
	<detailed_description>This open-label , Phase 1b dose escalation expansion study OMP-305B83 plus paclitaxel design evaluate safety , efficacy pharmacokinetics OMP-305B83 combination paclitaxel patient platinum resistant ovarian , primary peritoneal fallopian tube cancer . This study consist screen period , treatment period post-treatment follow period patient follow survival approximately 12 month . Patients enrol two stage : dose-escalation stage expansion phase . Approximately 30 patient enrol study approximately 5 study center United States ( U.S ) ..</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>1 . Platinum resistant Grade 2 3 ovarian , primary peritoneal fallopian tube cancer 2 . Measureable disease per response evaluation criterion ( RECIST ) v1.1 3 . Prior bevacizumab 4 . Age &gt; = 21 year 5 . Adequate organ marrow function 6 . For woman childbearing potential men partner childbearing potential , agreement ( patient and/or partner ) use two effective form contraception study entry least 6 month termination visit . 7 . Ability understand willingness sign write informed consent document 1 . Treatment anticancer therapy , include radiotherapy , chemotherapy , biologic therapy . Prior therapy weekly paclitaxel recurrent disease , unless administer 2 year prior enrollment , unless part upfront treatment strategy . 2 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess , clinical sign symptom gastrointestinaI obstruction know clinically signification gastrointestinal disease . 3 . Subjects brain metastases 4 . Subjects leptomeningial disease neoplasms last 5 year 5 . Blood pressure &gt; 140/80 6 . Significant intercurrent illness limit patient 's ability participate study 7 . Subjects know metastasis currently involve lumen gastrointestinal tract . 8 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior enrollment , anticipation need major surgical procedure course study 9 . Pregnant nursing woman 10 . New York Heart Association Classification II , III , IV 11 . Inability comply study follow procedure</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>